Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 4/20 | 0.63 |
| ▸ | MME | P08473 | 4/20 | 0.63 |
| ▸ | CASP3 | P42574 | 2/20 | 0.62 |
| ▸ | CASP1 | P29466 | 1/20 | 0.62 |
| ▸ | CASP9 | P55211 | 1/20 | 0.62 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.61 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6552944 | 1.00 | ECE1 (0.63) | ECE1MMECASP3CASP1CASP9 | |
| SCHEMBL14433746 | 1.00 | ECE1 (0.63) | ECE1MMECASP3CASP1CASP9 | |
| SCHEMBL6552949 | 1.00 | ECE1 (0.63) | ECE1MMECASP3CASP1CASP9 | |
| SCHEMBL13884433 | 1.00 | ECE1 (0.63) | ECE1MMECASP3CASP1CASP9 | |
| SCHEMBL14778231 | 0.96 | MME (0.63) | ECE1MMECASP3CASP1CASP9 | |
| SCHEMBL2873941 | 0.96 | MME (0.63) | ECE1MMECASP3CASP1CASP9 | |
| SCHEMBL13957718 | 0.95 | MME (0.64) | ECE1MMECASP3CASP1CASP9 | |
| SCHEMBL1426719 | 0.95 | MME (0.64) | ECE1MMECASP3CASP1CASP9 | |
| SCHEMBL13884435 | 0.95 | MME (0.64) | ECE1MMECASP3CASP1CASP9 | |
| SCHEMBL2181857 | 0.94 | CASP1 (0.62) | ECE1MMECASP3CASP1CASP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| US-7427639-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427639-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7211695-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7179794-B2 | Multivalent macrolide antibiotics | THERAVANCE, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179794-B2 | Multivalent macrolide antibiotics | THERAVANCE, INC. (US) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | ECE1 1010/4885MME 717/4885CASP3 4851/4885 |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2B | ECE1 961/4885MME 1148/4885CASP3 1691/4885 |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ECE1 961/4885MME 1148/4885CASP3 1691/4885 |
| US-20070154948-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | ECE1 415/4885MME 185/4885CASP3 3293/4885 |
| US-20090111737-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | ECE1 415/4885MME 185/4885CASP3 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.